Eikon Therapeutics (NASDAQ:EIKN), a clinical-stage biotechnology company focused on developing novel medicines through advanced imaging and machine learning platforms, reported corporate and clinical updates on March 30, 2026, alongside its full-year 2025 financial results.
The company successfully closed an upsized initial public offering that raised $381.2 million.
As of December 31, 2025, Eikon held $336 million in cash, cash equivalents and marketable securities, which it expects will be sufficient to fund operations into the second half of 2027.
Research and development and general and administrative expenses increased year-over-year, contributing to a net loss of $333.6 million for 2025.
Clinically, Eikon completed enrollment in the TeLuRide-005 Phase 2 trial of EIK1001, with data expected in the second half of 2026.
The Phase 1/2 programs for EIK1003 and EIK1004 continue to advance, with a new cohort start anticipated in the second half of 2026.
For EIK1005, the company completed the healthy volunteer study and has initiated the patient trial.